Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

WuXi PharmaTech Surprises with a 5% Q1 Revenue Increase

publication date: May 15, 2009
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

WuXi PharmaTech (药明康德) announced a 5% increase in Q1 revenues, but net income fell 15% and earnings per share dropped an even-greater 22% during the period. Stressing the positive, WuXi said its core business, China CRO laboratory services, rose a healthy 33%. The problem was in contract manufacturing, whose revenues sank by 81%. Evidently, WuXi has done a good job of preparing Wall Street for even worse results, because shares of WuXi moved sharply higher following the earnings announcement. More details...

Stock Symbol: (NYSE: WX)




Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners